The Comfort of Proactive Sleep Apnea Therapy

NCT ID: NCT06144892

Last Updated: 2024-03-07

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-25
• Study Completion Date: 2024-07-01

Brief Summary

The goal of this clinical trial is to compare in OSA patients who regularly adhere to CPAP therapy. The main question[s] it aims to answer are:

• To assess if proactive therapy can effectively treat OSA with lower mean therapy pressure compared to conventional APAP therapy
• To compare user comfort between proactive therapy and conventional APAP therapy

Participants will undergo the conventional APAP therapy and the new proactive therapy.

Researchers will compare nights in which conventional APAP was used and nights in which proactive therapy was used to see if patients were treated with lower pressures and effectively.

Detailed Description

This is a blinded, randomised, crossover, study on patients diagnosed with obstructive sleep apnea who regularly adhere to APAP therapy. Data collection will span 23 consecutive nights for each participant. Participants will use a modified APAP device for 2 periods of 9 nights each, separated by 5 nights in which participants will use their personal APAP device. The modified APAP device is switchable between two therapy modes: a) proactive therapy, and b) conventional APAP therapy. Treatment for the 2 periods will be randomly assigned, with one period as the test period where the proactive therapy is used every night for 9 consecutive nights, and the other as the control period where their conventional APAP therapy (i.e., the participant's regular therapy but on the modified device) is used every night for 9 consecutive nights. Participants will be blinded to the therapy they are receiving during the test and control period. Data will be collected by the modified PAP device and at-home sleep apnea test ring.

Conditions

Obstructive Sleep Apnea; Sleep Apnea

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Intervention first

Patients will undergo proactive therapy first, followed by the buffer period, and finally the conventional APAP therapy.

Group Type: EXPERIMENTAL

Proactive Therapy

Intervention Type: DEVICE

Uses AI to make predictions and preventions of future apneic events.

Control first

Patients will undergo the conventional APAP therapy first, followed by the buffer period, and finally the proactive therapy.

Group Type: EXPERIMENTAL

Proactive Therapy

Intervention Type: DEVICE

Uses AI to make predictions and preventions of future apneic events.

Interventions

Proactive Therapy

Uses AI to make predictions and preventions of future apneic events.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Must be a current CPAP user
• Must have used a PAP device for more than 4 months.
• Before the first night of the study, participant must be willing to lend their personal PAP device for inspection in order for the study coordinator to transfer their PAP therapy settings to one of our modified PAP devices.
• Must be willing to wear the sleep diagnostic ring throughout each night of the study for the entire study duration (i.e., the full 23 days).
• Must be willing to have their CPAP SD memory card analyzed to determine their mean pressure and excess leak rate history
• Must be free of flu-like illness or any upper tract infection symptoms at the time of data collection.

Exclusion Criteria

• Subjects actively using bi-level PAP or require oxygen therapy.
• Inspection of the participant's CPAP SD card data shows that history of highly frequent excess leak during therapy. Exclusion due to high leak will be determined on a case-by-case basis.
• History of severe cardiovascular disease, including NYHA Class III or IV heart failure, CAD with angina, or MI/stroke within past 6 months.
• Subjects who are medically complicated or who are medically unstable (i.e., cancer, dementia, unstable cardiac or respiratory disease, or unstable psychiatric illness)
• Potential sleep apnea complications that in the opinion of the clinician may affect the health and safety of the participant.
• Inability or unwillingness of individual to give written informed consent.
• Neuromuscular disease, hypoglossal-nerve palsy, severe restrictive or obstructive pulmonary disease, moderate-to-severe pulmonary arterial hypertension, severe valvular heart disease, New York Heart Association class III or IV heart failure, recent myocardial infarction or severe cardiac arrhythmias (within the past 6 months), persistent uncontrolled hypertension despite medication use, active psychiatric disease, and coexisting non-respiratory sleep disorders that would confound functional sleep assessment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

NovaResp Technologies Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

comfort study

Identifier Type: -

Identifier Source: org_study_id